Human papillomavirus (HPV) is the most frequently sexually transmitted agent in the world. It can cause cervical and other anogenital malignancies, and oropharyngeal cancer. HPV has the unique ability to persist in the host's epithelium for a long time-longer than most viruses do-which is necessary to complete its replication cycle. To this end, HPV has developed a variety of immune evasion mechanisms, which unfortunately also favor the progression of the disease from infection to chronic dysplasia and eventually to cancer. This article summarizes the current knowledge about HPV immune evasion strategies. A special emphasis lies in HPV-mediated changes of the antigen processing machinery, which is generating epitopes for T cells and contributes to the detectability of infected cells.
tions in principle are highly immunogenic. However, HPV replicates very slowly in comparison to other viruses. Therefore, it needed to develop effective immune evasion mechanisms, allowing the infection to persist long enough to complete the viral replication cycle. The natural immune control of an HPV infection is achieved by innate and adaptive immune responses including specific antibodies and effector T-cells. 10 Fortunately, the majority of HPV infections is cleared by the host immune system, even if this process takes 1-2 years from infection, and only a minority of infected individuals develops HPV-mediated cancer. 11 It is important to understand HPV immune evasion strategies to improve immunotherapeutic approaches, as so far they unfortunately have shown only limited success. 12, 13 Thus, this article wants to provide an update of the current state of research about immune evasion strategies used by HPV.
HPV Employs Multiple Immune Evasion Strategies on Different Intracellular Levels
The life cycle of HPV is the main principle used by this virus to stay undetected by the host. The virus has no secreted proteins; viral proteins are expressed at low levels during infection; the virus induces no inflammation; no viremia and also no host cell death. 8, 14 In addition, HPV does not cross the basement membrane where immune cells are more abundant. Therefore, it is not surprising that many naturally exposed individuals have a poor anti-HPV humoral immunity and an impaired T-cell immunity against the HPV proteins E2, E6 and E7 is observed in patients with high-grade CIN when compared to patients with regressed lesions. 15 The impaired immune response is the result of a broad and very effective spectrum of immune evasion strategies of HPV. In the following paragraphs, intracellular immune evasion strategies will be discussed, including alterations of gene expression, protein function and antigen processing. Subsequently, extracellular strategies that perturb immune cell functions are summarized.
Gene Expression
The DNA genome of HPV is small. Depending on the type, it has usually 8 open reading frames (ORFs) encoded by 8,000 base pairs. The HPV genome encodes for early (E1, E2, E4, E5, E6 and E7) and late (L1 and L2) genes depending on their expression during the viral life cycle. 16 
Low level gene expression
One immune evasion strategy of HPV is to keep the early viral gene expression at a low level, thus viral antigens are of very low abundance. Additionally, HPV proteins are nonsecreted. In the basal and lower layers of the epithelium, early gene expression is kept at low levels controlled by E2. Notably, during disease progression, when the HPV genome gets integrated, this often results in disruption of the E2 locus. From this time on, HPV E6 and E7 expression is rising. Thus, in high-grade lesions and cancer, the expression of E6 and E7 is no longer attenuated, which makes them ideal targets for immunotherapy. 17, 18 These low levels of viral protein expression can hinder detection of infected cells by local APCs and in turn the induction of a potent adaptive immune response directed against HPV-infected cells.
Virions only form in outmost epithelial layers, no lytic cell death
The highly immunogenic virions and a higher expression of viral proteins happen only in the upper epithelial layers. At this time point, infected keratinocytes have entered the terminal differentiation phase and virions will only be released by the natural process of cell shedding from the surface of the epithelium. 14, 15 In these layers close to the epithelial surface, immune cells have limited access, which is another advantage enabling HPV escape from immune recognition and reinfection.
Altered gene expression in host cells: Chemokines, adhesion molecules and TLRs HPV is also perturbing DNA methylation mechanisms to alter gene expression of the host cell. DNA methylation usually leads to downregulation of transcription. It is known that HPV E7 associates with DNMT1 (DNA methyltransferase 1) whereby the methyltransferase activity of the enzyme gets activated. 19 Recently, it has been demonstrated by Cicchini et al. that the promoter of CXCL14 is hypermethylated. This mechanism is dependent on E7. 20 CXCL14 is an important chemokine that orchestrates the attraction of multiple lymphocytes, among them natural killer (NK) cells, T cells, Langerhans cells (LCs) and dendritic cells (DCs). [20] [21] [22] Lately, there has been experimental evidence for an implication of E6 in the transcription of interferon (IFN)-j, a type I IFN only expressed in keratinocytes and DCs. The study showed that E6 contributed to de novo methylation near the transcriptional site of IFNj.
23 HPV16 E7 also induces E-cadherin promoter methylation. 24 E-cadherin is an adhesion molecule important for Langerhans cell movement through the stratified epithelium, and its loss causes LCs to leave the affected epithelium.
Besides DNA methylation, HPV has been described to alter histone modification. Histone modification is another epigenetic mechanism that can modulate gene expression. 25 For instance, Toll-like receptor (TLR)9 is downregulated by HPV38 E7. 26 In a normal physiological situation, TLR9 senses double-stranded DNA. HPV38 E7 recruits Polycomb protein enhancer of zeste homolog 2 (EZH2), which results in histone 3 trimethylation at lysine 27 (H3K27me3) in the TLR9 promoter region, and thus reduced TLR9 expression. Another mechanism for the downregulation of TLR9 by HPV16 E7 has been described by Hasan et al. 27 During infection of human epithelial cells, histone demethylase (JAR-ID1B) and histone deacetylase (HDAC1) are both recruited upstream of the transcriptional start site of the TLR9 gene leading to TLR9 downregulation, and thus diminished detection of viral DNA in infected cells.
Protein Function/Trafficking
The usual way of disturbing host protein function or trafficking by HPV oncogenes happens through protein-protein interaction. In this context, one has to understand that keratinocytes are regarded as immune sentinels. As a part of the skin, they belong to the first physical barrier that pathogens have to cross. Therefore, keratinocytes are able to induce multiple interferon responses and also express TLRs to alarm the immune system of invaders. 28 
Dysregulation of the keratinocyte IFN response
Interferon signaling is heavily dysregulated in HPV-infected keratinocytes by oncoprotein binding to interferon response factors (IRFs), which are transcription factors for interferoninduced genes. HPV16 and HPV18 E7 can bind to the transactivation domain of IRF1. 29, 30 In vivo, IRF1 responses are downregulated as a result of E7 expression leading to repressed TAP1, IFN-b and monocyte chemotactic protein 1 (MCP1). Similarly, IRF9 is targeted by HPV16 E7 through its IRF association domain (IAD). 31 During IFNa but not IFNg signaling, tyrosine kinase 2 (Tyk2) is inhibited by HPV18 E6 and weakly inhibited by HPV11 E6. 32 Thus, interferon responses are targeted by HPV at multiple points highlighting the importance of interferon signaling in antiviral immune responses.
Dysregulation of the cGAS-STING, TLR and NF-jB signaling pathways
Recently, it has been discovered that also the cGAS-STING (cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes) defense mechanism against DNA viruses can be targeted by HPV18 E7. 33 The cGAS-STING pathway was discovered in 2013 by Chen et al.
34 cGAS senses cytosolic DNA, then STING is recruited and induces an antiviral state within the cell. As already mentioned above, it was found that TLR9 expression and its function are diminished in cervical cancer. 35 TLR9 expression was induced again when the oncogenes E6 and E7 were knocked down. Another important pathway in regulating inflammation by cytokines, growth and survival factors is the NF-jB pathway. In cervical and also penile cancer, NF-jB expression was elevated and is thought to contribute in the development of chronic inflammation towards cancer. 36 In a recent study, it was shown that NF-jB inhibitors are beneficial in the treatment of HPV16-induced wasting syndrome in mice. 37 These data all show that HPV effectively blocks viral recognition.
Antigen Processing
Effective major histocompatibility factor (MHC) class-I antigen processing is indispensable for CD8
1 T-cell responses. The human homologue of MHC is human leukocyte antigen (HLA). CD8
1 T cells are often also referred to as cytotoxic T cells (CTL) because they can directly kill infected cells and are thus crucial in combating viral infections and antitumor responses. Therefore, viruses often target the antigen processing machinery (APM) to hinder T-cell recognition. Antigen processing starts in the cytosol with the degradation of intracellular proteins by the proteasome/immunoproteasome. The resulting peptides of a length of up to 16 amino acids are transported by the transporter associated with antigen processing (TAP) into the endoplasmic reticulum (ER). Here, peptides are cleaved by endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to their optimal length for HLA binding. Peptide loading to HLA class-I is assisted by chaperones such as calnexin and tapasin. 38 In recent years, numerous descriptions of altered antigen processing in HPV infections and HPV-induced cancer have been published. HPV has been found to disturb multiple components of the APM, thereby directly interfering with the effective generation of CTL epitopes.
Proteasome
The proteasome is the cytosolic protein degradation machinery. Proteins destined for degradation within a cell, irrespective whether of cellular or foreign (e.g., viral) origin, are cleaved into peptides. The proteolytic subunits of the proteasome are replaceable by IFNg-inducible subunits to form immunoproteasomes. The immunoproteasome subunits PSMB8 and PSMB9 in the cytoplasm have a decreased expression in cells infected with HPV16. 39 PSMB9 expression has been found to be repressed by HPV16 and HPV18 E7, 40 whereas the promoter of the PSMB8 gene has been observed to be highly methylated in HPV16-positive cervical cancer. 41 
Peptide loading
The TAP transporter can be affected by HPV as well. In cervical cancer, the expression of TAP1 and TAP2 was reported to be repressed. TAP1 transcription can be inhibited by HPV16 E7 and additionally its promoter is highly methylated in HPV16-positive cervical cancer. 39, 41 Furthermore, a loss or a partial loss of MHC class-I, calreticulin, calnexin, ERAP1, PDIA3 and tapasin protein expression was described in cervical cancer. 41 Altered APM component expression leads to changes in HPV epitope presentation. For instance, Evans et al. reported that presentation of the HPV16-derived epitope E6 [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] is dependent on TAP, and TAP was expressed at low levels in a cervical carcinoma cell line. 39 This study demonstrated for the first time in the context of HPV-induced malignancies that changes in the APM are correlated with functional consequences in anti-HPV CTL responses.
Aminopeptidases
The aminopeptidase ERAP1 has been recognized as a key player in epitope editing 42 and its expression has been studied in multiple cancers in recent years. These studies found highly varying levels in different tumors. [43] [44] [45] [46] In cervical cancer, Mehta et al. observed a downregulation of ERAP1 in 15% of investigated samples, 47 and that ERAP1 variants were correlated with increased metastases and decreased survival. 47, 48 On the other hand, ERAP1 has also been found to be overexpressed in several tumor entities, [43] [44] [45] [46] including cervical cancer. 49 In line with these results, we recently reported that ERAP1 is overexpressed in cervical intraepithelial lesions (CINs) and cervical cancer. 50 ERAP1 overexpression was found to be increasing with disease state, likely causing progressive destruction of epitopes. Indeed, ERAP1 overexpression led to reduced HPV16-specific CD8 1 T-cell responses.
Importantly, attenuation of ERAP1 overexpression resulted in enhanced HPV16-specific CTL-mediated tumor cell killing. 50 
MHC surface expression
The expression of MHC class-I (MHC-I) is impaired on the transcriptional level and during its trafficking to the cell surface. E7 has been shown to directly block the MHC-I heavy chain promoter. 40 HLA-A and -B can be retained by an HPV16 E5-mediated mechanism within the cell. [51] [52] [53] [54] On the contrary, HLA-C and HLA-E are not influenced by E5. The hydrophobic region of the E5 protein can interact with leucine pairs in the first transmembrane domain of the MHC-I heavy chain. Alternatively, E5 keeps MHC-I in the Golgi apparatus by vesicle alkalinization. A third mechanism has been described as well. HPV16 E5 can bind to calnexin, which assists correct folding of the nascent MHC-I, thereby keeping MHC-I in the ER. Many studies presented further data on APM defects in cervical and head and neck cancer. 40, 41, 47, 55, 56 However, in this context, one has to bear in mind that only 20-30% of head and neck cancers are HPV positive.
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Extracellular HPV Immune Evasion Strategies Affecting Immune Cell Function
In addition to intracellular immune evasion mechanisms, HPV is also able to perturb cellular immune networks that are crucial to effectively clear the virus. HPV efficiently hampers APCs such as DCs and Langerhans cells, and effector cells including NK and T-cells. Almost all immune evasion strategies are present during infection and in HPV-driven tumors. Still, besides the immune evasion strategies during infection, HPV-driven tumors employ additional strategies to hide from the host immune system.
Antigen presenting cells
The crucial link between the innate and the adaptive immune system are antigen presenting cells (APCs) and exactly these are inhibited by HPV. Langerhans cells are immature DCs resident in the epidermis and superficial epithelial layers of the mucosa. They induce adaptive immune responses by detecting viral structures via pattern recognition through their TLRs. 58 In 2002, Kast et al. observed that LCs are not activated by HPV virus-like particles (VLPs) and could not prime T cells. 59 As a consequence of the E-cadherin downregulation on infected keratinocytes (described above), 24 LCs leave the infected tissue. Recently, it was demonstrated in a mouse model that the E7 protein alone is also sufficient to reduce LCs in the skin. 60 
T cells
For the effective clearance of HPV, a robust T-helper (Th) cell and cytotoxic T-cell (CTL) response is needed. 61 There are two types of Th responses, Th1 and Th2. Th1 responses are usually directed against intracellular pathogens and promote a proinflammatory response, whereas Th2 responses are usually induced in infections with extracellular pathogens, play a role in allergic reactions and are not proinflammatory. Interestingly, it has been unraveled that HPV is able to interfere with Th1/Th2 polarization of the immune response. 62 In early HPV-induced lesions, cytokines associated with a Th2-like immune response such as interleukin (IL)-6 and IL-10 are detected and only low or no IFNg-mediated Th1 responses. On the contrary, high-grade epithelial lesions have upregulated levels of tumor necrosis factor (TNF)-a and elevated levels of both Th1 and Th2 associated cytokines, reflecting an uncoordinated immune response in advanced disease. The shift from Th1 to Th2 during the early lesions may perturb proper virus immune recognition and thus promote disease persistence and progression. 62, 63 Tumor-associated macrophages, myeloid-derived suppressor cells and regulatory T cells
To evade immune recognition, HPV-driven tumors create an immunosuppressive environment similar to many other tumor types. Immunosuppressive cell types such as tumorassociated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs) are recruited to infiltrate the tumor. 64, 65 The heterogeneous population of TAMs mostly consists of macrophages with an M2-like phenotype. These are known to inhibit antitumor T-cell responses, attract Tregs and secrete the immunosuppressive cytokines IL-10 and tumor growth factor-beta (TGFb). 64 MDSCs produce reactive oxygen species (ROS). Although the role of MDSCs in HPV-driven tumors has not been fully elucidated, it is believed that ROS cause inhibition of T-cell activation by downregulating the CD3f-chain of the TCR complex. 66 In addition, Tregs, important players of peripheral tolerance, secrete immunosuppressive cytokines such as IL-10 and TGFb and can directly inactivate T cells for example by surface-expressed CTLA-4.
Conclusion
Taken together, HPV is evolutionary such a successful virus because of its ability to stay undetected by the host's immune system for extended periods of time. Passively, HPV evades the immune system by its normal life cycle being located completely outside the epithelial basement membrane, not eliciting any danger signals. Active immune evasion of HPV is mediated intracellularly by altered gene expression and disturbed protein functions, and extracellularly by interfering with immune cell networks from antigen presenting cells to effector T cells. Already during early infection, the suppressed IFN and cGAS-STING responses inhibit the induction of an antiviral state. Later immune evasion mechanisms, such as downregulation of TLRs and adhesion molecules on the infected host cell, and decreased chemokine production by the infected keratinocytes lead to reduced attraction of professional antigen presenting cells and thus to a delay in triggering anti-HPV immune responses. Subsequently, low viral protein expression levels and interference with antigen processing contribute to decreased HPV epitope presentation and therefore to impeded detection of infected cells by T cells. All these strategies permit HPV to persist for a long time, which allows the virus to complete its life cycle, but also increases the risk of lesion persistence and the onset of malignant transformation. Fortunately, most HPV infections and lesions are cleared by the host immune system eventually. Clearance is mediated by effector T cells, and anti-HPV immunotherapies seek to enhance these responses in individuals that did not spontaneously clear the infection. To improve current immunotherapeutic approaches, a better understanding of HPV immune evasion mechanisms at all stages of infection is important.
